<?xml version="1.0" encoding="UTF-8"?>
<p>Due to these risks of certain phthalates to health, in March 2012, the CDER published a guide to orient the pharmaceutical industry on the use of phthalates: “Limiting the use of certain phthalates as excipients in CDER regulated products”. This guidance document recommends limiting the use of certain phthalates, such as dibutyl phthalate (DBP) and di(2-ethylhexyl) phthalate (DEHP) [
 <xref rid="B28-pharmaceutics-13-00387" ref-type="bibr">28</xref>].
</p>
